Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Annals of Surgical Treatment and Research ; : 145-150, 2015.
Article in English | WPRIM | ID: wpr-26224

ABSTRACT

PURPOSE: The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection. METHODS: We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA. RESULTS: Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died. CONCLUSION: HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.


Subject(s)
Humans , DNA , Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis B , Hepatitis , Immunoglobulins , Liver Transplantation , Liver , Prognosis , Recurrence , Retrospective Studies , Survival Rate , Tissue Donors , Transplants
2.
Gut and Liver ; : 363-366, 2011.
Article in English | WPRIM | ID: wpr-205658

ABSTRACT

BACKGROUND/AIMS: The exclusion of hepatitis B core antibody (HBcAb)-positive donors from liver transplants (LTs) due to the risk of transmitting hepatitis B virus (HBV) does not appear to be practical in Korea, where hepatitis B is endemic. This study assessed the risk of de novo HBV infection in hepatitis B surface antigen (HBsAg)-negative LT recipients receiving a liver from HBcAb-positive donors. METHODS: Of 341 adult living donor LTs conducted at our institution between March 2001 and September 2008, 176 donors (51.6%) were HBcAb-positive, and 26 HBcAb-positive grafts were transplanted to HBsAg-negative recipients. The median follow-up time after LT was 41.9 months. RESULTS: Without anti-HBV prophylaxis, 2 out of 26 (7.7%) HBsAg-negative recipients who received grafts from HBcAb-positive donors developed de novo HBV infection 20 and 85 months after LT. These patients had been negative for all HBV serologic markers before transplantation. In both cases, there were no abnormalities in liver function tests upon diagnosis of de novo HBV infection. CONCLUSIONS: De novo HBV infection from HBcAb-positive donors after LT does not appear to be of great concern in terms of the number of cases in Korea because high risk patients who are HBV-negative comprise only a small proportion of the recipients. However, HBV-naive LT recipients still carry the risk of developing de novo HBV infection as in non-HBV endemic areas.


Subject(s)
Adult , Humans , Follow-Up Studies , Hepatitis , Hepatitis B , Hepatitis B Surface Antigens , Hepatitis B virus , Korea , Liver , Liver Function Tests , Liver Transplantation , Living Donors , Tissue Donors , Transplants
3.
Gut and Liver ; : 248-252, 2011.
Article in English | WPRIM | ID: wpr-98935

ABSTRACT

A 60-year-old woman with end stage liver cirrhosis caused by genotype 2 hepatitis C virus (HCV) infection received an orthotopic liver transplantation (OLT). The patient was negative for the hepatitis B surface antigen (HBsAg) and positive for the anti-hepatitis B surface antibody (anti-HBs) prior to and one and a half months following the OLT. Due to reactivation of hepatitis C, treatment with interferon-alpha and Ribavirin started two months following the OLT and resulted in a sustained virological response. We performed a liver biopsy because a biochemical response was not achieved. Surprisingly, liver pathology showed HBsAg-positive hepatocytes with a lobular hepatitis feature, which had been negative in the liver biopsy specimen obtained one and a half months post-OLT. High titers of both HBsAg and HBeAg were detected, while anti-HBs antibodies were not found. Tests for IgM anti-hepatitis B core antibody and anti-delta virus antibodies were negative. The serum HBV DNA titer was over 1x10(7) copies/mL. A sequencing analysis showed no mutation in the "a" determinant region, but revealed a mixture of wild and mutant strains at an overlapping region of the S and P genes (S codon 213 (Leu/Ile); P codons 221 (Phe/Tyr) and 222 (Ala/Thr)). These findings suggest that de novo hepatitis B can develop in patients with HCV infection during the post-OLT period despite the presence of protective anti-HBs.


Subject(s)
Female , Humans , Middle Aged , Antibodies , Biopsy , Codon , DNA , Genotype , Hepacivirus , Hepatitis , Hepatitis B , Hepatitis B e Antigens , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis C , Hepatocytes , Immunoglobulin M , Interferon-alpha , Liver , Liver Cirrhosis , Liver Transplantation , Ribavirin , Superinfection , Viruses
4.
The Journal of the Korean Society for Transplantation ; : 73-79, 2010.
Article in Korean | WPRIM | ID: wpr-49931

ABSTRACT

The growing shortage of organs for orthotopic liver transplantation (OLT) has led to an expanded donor pool with the use of marginal grafts. Recipients who receive liver grafts from HBsAg-negative, anti-HBc positive donors have an increased risk of developing de novo hepatitis B infection. This review covers several issues in liver transplantation using hepatitis B core antibody-positive donors: (1) the mechanism of de novo hepatitis B infection, (2) high risk groups, (3) prophylactic regimens and (4) clinical significance and a proposal for patients in Korea.


Subject(s)
Humans , Hepatitis , Hepatitis B , Korea , Liver , Liver Transplantation , Tissue Donors , Transplants
5.
Korean Journal of Pediatric Gastroenterology and Nutrition ; : 32-38, 2003.
Article in Korean | WPRIM | ID: wpr-117996

ABSTRACT

PURPOSE: Hepatic allografts from donors with hepatitis B core antibody have been demonstrated to transmit hepatitis B virus (HBV) infection to recipients after liver transplantation (LT). The efficacy of hepatitis B immune globulin (HBIg) to prevent de novo hepatitis B was investigated by comparing active immunization in the early phase to HBIg monotherapy in the late phase of pediatric liver transplants at Samsung Medical Center. METHODS: Among pediatric liver transplants, from May, 1996 to June, 2002, 15 recipients who were hepatitis B surface antigen (HBsAg) (-) received an allograft from a donor with hepatitis B core antibody (HBcAb) (+). Except two who died from unrelated causes, eleven of 13 recipients were HBsAb (+), and 2 were naive (HBsAb(-), HBcAb(-)). All patients were vaccinated for HBV before LT. In the early phase (January, 1997~November, 1997, 3 patients), HBsAb (+) recipients received booster vaccination after LT. In the late phase (December, 1997~, 10 patients), all recipients were given booster vaccination and received HBIg therapy in order to maintain HBsAb titer greater than 200 IU/L. Lamivudine was given in one case because of severe side effect of HBIg. We retrospectively analyzed the effect of the preventive therapy for de novo hepatitis B through medical records. RESULTS: De novo hepatitis B developed in three of 13 recipients (23.1%). All of 3 patients who received active immunization in the early phase became HBsAg (+) at 7~19 months after transplantation. One of them was naive before LT and the other two were HBsAb (+). All of 10 recipients who were given HBIg in the late phase remained HBsAg (-) at 7~55 months' follow-up. CONCLUSION: Passive immunization with HBIg was effective for prevention of de novo hepatitis B in HBsAg (-) recipients of hepatic allografts from HBcAb (+) donors.


Subject(s)
Humans , Allografts , Follow-Up Studies , Hepatitis B Surface Antigens , Hepatitis B virus , Hepatitis B , Hepatitis , Immunization, Passive , Lamivudine , Liver Transplantation , Liver , Medical Records , Retrospective Studies , Tissue Donors , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL